Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
about
Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularizationOptimal combination of antiangiogenic therapy for hepatocellular carcinomaAnti-angiogenic gene therapy in the treatment of malignant gliomasDynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel densityEffects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2Dexamethasone alleviates tumor-associated brain damage and angiogenesisSensitivity of MRI tumor biomarkers to VEGFR inhibitor therapy in an orthotopic mouse glioma modelInteraction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailabilityEndothelial Thermotolerance Impairs Nanoparticle Transport in Tumors.Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma modelHearing improvement after bevacizumab in patients with neurofibromatosis type 2Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.Glioma-related edema: new insight into molecular mechanisms and their clinical implications.Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.An efficient computational approach to characterize DSC-MRI signals arising from three-dimensional heterogeneous tissue structuresPhase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.Measuring Vascular Permeability In VivoAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Advances in MRI assessment of gliomas and response to anti-VEGF therapy.Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical modelsVascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristineDoes age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastomaVascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in GlioblastomaPhase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaAntitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity.Experimental approaches for the treatment of malignant gliomas.In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model.Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.Association of pSTAT3-VEGF signaling pathway with peritumoral edema in newly diagnosed glioblastoma: an immunohistochemical study.C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells
P2860
Q26781833-537D1152-BFC7-4D55-BAFB-30F88CF5FB7DQ26799458-09EFAFB3-722E-4054-81D6-86ADE429970DQ26866276-BF261E51-50A9-4615-843A-701999C67203Q27308856-6E20B7E0-97A2-4AED-ABAB-194CAFD464EFQ28487568-2D07ED43-AA22-411C-91C4-58E631A520F2Q28542092-0E72135D-591C-466A-80E1-5260338962D5Q28742242-CD11C899-E094-4400-ACA6-229FC0B5F0C1Q29012696-5BEF1182-2422-4CE8-BD57-4970E05CFEC8Q30376502-8E81CF6D-862B-4652-962B-073A0A06A720Q30383248-FFCFA79A-D0A7-4E31-B30E-35F1B60122E9Q30387415-5582DE1D-F4CA-4734-8105-62E1EA041EA1Q30388655-23CC5997-7A9D-409D-8300-E89CEA2A3B9BQ30417015-240BC24E-3E34-4AEF-9C79-4F7861E77950Q30469815-B6B6CA5F-4876-46D0-9355-84B4455E916EQ30471456-C445A3D0-3CCC-4FAB-8953-9F04AB58BCFBQ30493217-67AC2618-ECC5-4CA3-8877-375697D622F6Q30581454-5996E867-DBEF-49FC-82FC-FEEE79D6D69AQ30651792-2995DED5-AC0F-4164-A8FA-B845ABB8B562Q30731774-C2F47F67-3DC7-47CB-A624-24A8AE89455BQ33388438-E5EFB3D5-EFBE-47D3-8D36-5ECC0FE612E2Q33427833-F3BAACD3-699D-4008-B866-34D94EEF052EQ33504611-D18BC9E6-DF16-4CC6-A1B0-30578A208BDEQ33518926-0218BA7A-FB2F-4239-AA3A-881CACEE5672Q33587106-80CFA2E6-67E8-41D0-8376-3C44AE30C7DDQ33644407-44F52B2C-2A38-41C7-A1C5-7460133D7457Q33699854-E5212F66-53BD-4F1A-A429-C8494463354CQ33770680-A8C832D4-6B65-43AA-A63F-D089FFB306EFQ33793253-36BA5ED6-5750-47AD-B46E-3F0E9BAB16C6Q33807228-60130BC9-77FD-4675-8FBA-28072903521EQ33811126-D4CA7DCD-9773-4FC9-9CFA-D3C7EAAB3A61Q33866374-0DF95887-2121-4CA8-B3B6-3F11A22F08CBQ33868332-B13BDCFB-109E-474A-B22C-8342414F52E8Q33868524-E9553828-8102-4198-8ACC-B5BB3B4DB07CQ33990834-9B59A8EC-E302-45A9-A780-F11C4CB2E17CQ34023502-F6175535-5612-41F5-BF46-A8B15D1F7A45Q34127138-0737DF5E-19CB-4A85-A3DF-FA1CB279F994Q34132818-B641C75E-962E-4F3B-80D7-CEEC523C3D75Q34331739-94AD8C61-A0FD-41E2-9CFC-AA70FE40016DQ34371631-45803749-2429-4125-932A-C55882AAB2A1Q34471954-95AC36FA-F486-43D2-8F15-864B91ED70B1
P2860
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Edema control by cediranib, a ...... nt brain tumor growth in mice.
@ast
Edema control by cediranib, a ...... nt brain tumor growth in mice.
@en
type
label
Edema control by cediranib, a ...... nt brain tumor growth in mice.
@ast
Edema control by cediranib, a ...... nt brain tumor growth in mice.
@en
prefLabel
Edema control by cediranib, a ...... nt brain tumor growth in mice.
@ast
Edema control by cediranib, a ...... nt brain tumor growth in mice.
@en
P2093
P2860
P356
P1476
Edema control by cediranib, a ...... nt brain tumor growth in mice.
@en
P2093
A Gregory Sorensen
Annique M Duyverman
Carsten D Ley
Christian T Farrar
Dai Fukumura
Dan G Duda
Delphine A Lacorre
Emmanuelle di Tomaso
Johanna Lahdenranta
Lance L Munn
P2860
P304
P356
10.1200/JCO.2008.19.9356
P407
P577
2009-03-30T00:00:00Z